Company: CMND
Filing Date: 2025-06-12
Form Type: POS AM
Source: 0001213900-25-053898
Chunk: 13

Company: Clearmind Medicine Inc.
Filing Date: 2025-06-12
Form: POS AM
Chunk 13
---
 section of this prospectus titled “Use of Proceeds.”                     |
| Risk factors                                                                                                  |     | Investing in our securities involves a high degree of risk. You should read the “Risk Factors” section starting on page 5 of this prospectus and “Item 3. - Key Information – D. Risk Factors” in our annual report on Form 20-F for the year ended October 31, 2024, or the 2024 Annual Report, incorporated by reference herein, and other information included or incorporated by reference in this prospectus for a discussion of factors to consider carefully before deciding to invest in our common shares. |
| Nasdaq Capital Market symbol                                                                                  |     | “CMND”                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Frankfurt Stock Exchange symbol                                                                               |     | “CWY”                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

Unless otherwise stated, all information in this prospectus is based on 5,379,441 common shares outstanding as of June 11, 2025, and does not include the following as of that date:

| ● | 2,238,848 common shares issuable upon the exercise                                                                                 
 of warrants outstanding as of such date, at exercise prices ranging from $1.0777 to $243.75, all of which were vested as of such   
 date;                                                                                                                              |
| ● | 5,521 common shares issuable upon the exercise of                                                                                  
 options to directors, employees and consultants under our incentive option plan outstanding as of such date, at a weighted average 
 exercise price of $435.64, of which 5,504 were vested as of such date; and                                                         |
| ● | 1,251 common shares issuable upon the exercise of                                                                                  
 restricted share units issued to consultants under consulting agreements.                                                          |

Unless otherwise indicated, all information in this prospectus assumes or gives effect to no exercise of the warrants or options described above See “Description of Share Capital” for additional information.

<div align='center'>4

RISK FACTORS</div>

You should carefully consider the risks described below and the risks described in our 2024 Annual Report which are incorporated by reference herein, as well as the financial or other information included in this prospectus or incorporated by reference in this prospectus, including our consolidated financial statements and the related notes, before you decide to buy our securities. The risks and uncertainties described below are not the only risks facing us. We may face additional risks and uncertainties not currently known to us or that we currently deem to be immaterial.